AI Article Synopsis
- The purpose of the pilot project was to evaluate the feasibility of using an electronic patient-reported outcomes (ePRO) system to monitor symptoms, adherence, and financial concerns for patients starting oral chemotherapy, especially in the context of increased remote care needs due to COVID-19.
- Results showed that patients using the ePRO system had a quicker time to first symptom assessment (3 days) compared to a historical cohort (7 days), demonstrating that the ePRO tool could enhance monitoring efficiency.
- Although there were no significant differences in emergency department visits or hospitalizations between the ePRO group and the historical group, the study concludes that a systematic ePRO approach is feasible and suggests further research to improve patient engagement and assess long
Article Abstract
Purpose: Oral chemotherapy challenges providers' abilities to safely monitor patients' symptoms, adherence, and financial toxicity. COVID-19 has increased the urgency of caring for patients remotely. Collection of electronic patient-reported outcomes (ePROs) has demonstrated efficacy for patients on intravenous chemotherapy, but limited data support their use in oral chemotherapy. We undertook a pilot project to assess the feasibility of implementing an ePRO system for patients starting oral chemotherapy at our cancer center, which includes both an academic site and a community site.
Methods: Patients initiating oral chemotherapy were asked to participate. A five-question tool was built in REDCap. Concerning responses triggered outreach within one business day. The primary outcome was time to first symptom assessment. For comparison, we used a historical cohort of patients who had been prescribed oral chemotherapies by providers in the same disease groups at the cancer center.
Results: Twenty-five of 62 (40%) patients completed ePRO assessments. Fifty historical charts were reviewed. Time to first symptom assessment was 7 days (IQR, 4-14 days) in the historical group compared with 3 days (IQR, 2-4 days) in the ePRO group. Time to clinical action was 14 days (7-35 days) in the historical group compared with 8 days (4-19 days) in the ePRO group. No statistically significant differences were detected in 30-day emergency department visit or hospitalization (12% for both groups) or 90-day emergency department visit or hospitalization rates (historical 28% and ePRO 20%).
Conclusion: An ePRO tool monitoring patient concerns about adherence, cost, and toxicities for patients with new oral chemotherapy regimens is feasible and improves time to symptom assessment. Further investigation is needed to improve patient engagement with ePROs and evaluate the long-term impacts for patients on oral chemotherapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1200/CCI.20.00191 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
High-Cost Cancer Drug Use in Medicare Advantage and Traditional Medicare.
JAMA Health Forum
January 2025
Department of Health Systems, Management, and Policy, University of Colorado Cancer Center, Aurora.
Importance: Medicare Advantage (MA) plans are designed to incentivize the use of less expensive drugs through capitated payments, formulary control, and preauthorizations for certain drugs. These conditions may reduce spending on high-cost therapies for conditions such as cancer, a condition that is among the most expensive to treat.
Objective: To determine whether patients insured by MA plans receive less high-cost drugs than those insured by traditional Medicare (TM).
A systematic review of salivary gland hypofunction and/or xerostomia induced by non-surgical cancer therapies: prevention strategies.
Support Care Cancer
January 2025
Department of Dentistry and Oral Health, Faculty of Health, Aarhus University, Aarhus, Denmark.
Purpose: This systematic review aimed to assess the updated literature for the prevention of salivary gland hypofunction and xerostomia induced by non-surgical cancer therapies.
Methods: Electronic databases of MEDLINE/PubMed, EMBASE, and Cochrane Library were searched for randomized controlled trials (RCT) that investigated interventions to prevent salivary gland hypofunction and/or xerostomia. Literature search began from the 2010 systematic review publications from the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) up to February 2024.
Comparative Evaluation of Two Novel Natural Desensitizing Agents on Dentinal Tubule Occlusion: A Scanning Electron Microscopy Study.
J Contemp Dent Pract
September 2024
Department of Conservative Dentistry and Endodontics, PMNM Dental College and Hospital, Bagalkot, Karnataka, India.
Aim: The present study is aimed to compare the effectiveness of dentinal tubule occlusion of two natural-based desensitizing toothpaste (Bentodent Desensitizer and Fang Farm Mint) and Novamin-based toothpaste (Shy-NM) under scanning electron microscope (SEM).
Materials And Methods: A total of 60 root dentin discs (3 mm-thick) were obtained from recently extracted permanent premolar teeth and were randomly divided into four groups based on the desensitizing toothpaste used, each group with 15 samples: Group I: Control, group II: Shy-NM, group III: Bentodent desensitizer, group IV: Fang Farm Mint. Samples were brushed for 2 min twice daily with a soft toothbrush with respective pea size amount of toothpaste for 14 days manually.
Heteronemin suppresses EGF‑induced proliferation through the PI3K/PD‑L1 signaling pathways in cholangiocarcinoma.
Oncol Rep
March 2025
Graduate Institute of Nanomedicine and Medical Engineering, College of Medical Engineering, Taipei Medical University, Taipei 11031, Taiwan, R.O.C.
Epidermal growth factor (EGF) binds with its surface receptor to stimulate gene expression and cancer cell proliferation. EGF stimulates cancer cell growth via phosphoinositide 3‑kinase (PI3K) and programmed cell death ligand 1 (PD‑L1) pathways. As an integrin αvβ3 antagonist, heteronemin exhibits potent cytotoxic effects against cancer cells.
View Article and Find Full Text PDFEffect of Oral Posaconazole on Venetoclax Plasma Concentration and its Efficacy in Patients with Acute Myeloid Leukemia.
Recent Pat Anticancer Drug Discov
January 2025
Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, 510282, P.R. China.
Background: BCL-2 was the first gene identified to have antiapoptotic effects, and venetoclax is an oral selective BCL-2 inhibitor, which has great potential in the treatment of patients with acute myeloid leukemia (AML) who are not candidates for intensive therapy. Notably, posaconazole, an oral antifungal drug, is also a strong factor that can affect blood venetoclax concentrations. To the best of our knowledge, the relationship between BCL-2 expression, posaconazole, and venetoclax, as well as their influence on treatment efficacy and the prognosis of patients with AML, has not been reported.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!